Novaremed Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $50M

  • Investors
  • 3

Novaremed General Information

Description

Developer of pharmaceutical drugs using small bio-molecules designed for the treatment of neuropathic pain. The company develops an orally active non-opioid small molecule with a novel mechanism of action against podoplanin (PDPN), which is a tyrosine kinase modulator to be used for the treatment of neuropathic pain, enabling doctors and healthcare organizations to treat neuropathy-related diseases, especially diabetic neuropathic pain, effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Thiersteinerallee 17
  • 4053 Basel
  • Switzerland
+41 061
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Thiersteinerallee 17
  • 4053 Basel
  • Switzerland
+41 061

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novaremed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 28-Jan-2021 $50M Completed Clinical Trials - Phase 2
7. Later Stage VC 15-Sep-2020 Completed Clinical Trials - Phase 2
6. Later Stage VC 02-Sep-2019 Completed Clinical Trials - Phase 2
5. Later Stage VC 23-Aug-2018 Completed Clinical Trials - Phase 2
4. Later Stage VC 17-Apr-2018 Completed Clinical Trials - General
3. Early Stage VC Completed Clinical Trials - General
2. Accelerator/Incubator 23-Jan-2009 $617K $617K Completed Clinical Trials - General
1. Grant 01-Nov-2008 $1.14M Completed Clinical Trials - General
To view Novaremed’s complete valuation and funding history, request access »

Novaremed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 606,452 $0.109923 $10.83 $10.83 1x $10.83 16.83%
Ordinary 453,179 $0.109923 $10.77 $10.77 1x $10.77 12.58%
To view Novaremed’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Novaremed Patents

Novaremed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026037478-A1 (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain Pending 11-Aug-2023
EP-3939578-A1 Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease Inactive 13-Jul-2020
AU-2020210831-A1 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity Active 23-Jan-2019
AU-2020210831-B2 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity Active 23-Jan-2019
EP-3860582-A1 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity Active 23-Jan-2019 C07C233/22
To view Novaremed’s complete patent history, request access »

Novaremed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novaremed Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Global Emerging Markets PE/Buyout Minority
Gefen Biomed Investments Venture Capital Minority
Biomedix Incubator Accelerator/Incubator Minority
To view Novaremed’s complete investors history, request access »

Novaremed Acquisitions (1)

Novaremed’s most recent deal was a Merger/Acquisition with Metys Pharmaceuticals. The deal was made on 07-Sep-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Metys Pharmaceuticals 07-Sep-2021 Merger/Acquisition Drug Discovery
To view Novaremed’s complete acquisitions history, request access »

Novaremed FAQs

  • When was Novaremed founded?

    Novaremed was founded in 2008.

  • Where is Novaremed headquartered?

    Novaremed is headquartered in Basel, Switzerland.

  • What is the size of Novaremed?

    Novaremed has 10 total employees.

  • What industry is Novaremed in?

    Novaremed’s primary industry is Drug Discovery.

  • Is Novaremed a private or public company?

    Novaremed is a Private company.

  • What is Novaremed’s current revenue?

    The current revenue for Novaremed is .

  • How much funding has Novaremed raised over time?

    Novaremed has raised $75.2M.

  • Who are Novaremed’s investors?

    Global Emerging Markets, Gefen Biomed Investments, and Biomedix Incubator have invested in Novaremed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process